Core Viewpoint - Multiple companies, including Tencent Holdings and China Hongqiao, conducted share buybacks on August 20, 2025, with Tencent leading in both volume and monetary value [1]. Group 1: Buyback Details - Tencent Holdings (00700) repurchased 934,000 shares for a total of 551 million [2]. - China Hongqiao (01378) repurchased 3,318,000 shares for a total of 784.03 million [2]. - Other notable buybacks include: - Techtronic Industries (00669): 250,000 shares for 25.19 million [2]. - Hang Seng Bank (00011): 200,000 shares for 22.37 million [2]. - Guochuang Tongqiao-B (02190): 100,000 shares for 2.32 million [2]. Group 2: Year-to-Date Buyback Performance - Year-to-date buyback totals for selected companies include: - Tencent Holdings: 40,267,000 shares, representing 0.438% of total shares [2]. - China Hongqiao: 52,641,500 shares, representing 0.560% of total shares [2]. - Techtronic Industries: 750,000 shares, representing 0.041% of total shares [2]. - Other companies with significant year-to-date buybacks include: - Maple Leaf Education (01317): 4,903,200 shares, representing 1.650% of total shares [2]. - Yanzheng Technology (02488): 2,190,500 shares, representing 1.356% of total shares [2].

Group 1 - The company, Guichuang Tongqiao, repurchased 100,000 shares at an average price of HKD 23.20, totaling approximately HKD 2.32 million, with a cumulative repurchase of 4.0145 million shares this year, representing 1.26% of the total share capital [1] - As of the market close on the same day, Guichuang Tongqiao's stock price decreased by 1.18%, closing at HKD 23.38 per share [1] - Stock repurchase is typically a strategy employed by management when they believe the company's stock is undervalued, indicating confidence in future development despite market perceptions [1] Group 2 - Guichuang Tongqiao is an innovative medical device company listed on the Hong Kong Stock Exchange, focusing on the research, production, and sales of neuro and peripheral vascular interventional medical devices [2] - The company invests significantly in technology research and development, holding a series of proprietary technologies, and its product range includes various interventional medical devices such as stents [2] - With the growing demand for interventional treatments in the medical industry, Guichuang Tongqiao faces opportunities for development while also needing to address market competition and technological advancements [2]

智通财经APP讯，归创通桥(02190)公布，2025年8月20日耗资约232.03万港元回购10万股股份。 ...

格隆汇8月20日丨归创通桥(02190.HK)公告，8月20日耗资232万港元回购10万股。 ...

归创通桥(02190)公布，2025年8月20日耗资约232.03万港元回购10万股股份。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歸創通橋醫療科技股份有限公司 呈交日期： 2025年8月20日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02190 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | ...

展望未来，归创通桥表示，公司将坚守"为生命恒创新"的使命，持续发挥全产品解决方案与精益运营的 优势，依托集采稳步扩大市场份额；加快国际业务布局，提升全球市场覆盖；聚焦具有真正临床价值的 差异化创新产品开发，实现公司长期稳健发展，助力全球医疗健康科技的创新与进步。 具体来看，归创通桥表示，上半年，公司依托丰富且高品质的产品组合，在专业及高效的商业化团队推 动下，延续多轮集采中标的良好态势，实现销售规模快速增长。报告期内，公司通桥银蛇颅内中间导管 系列、神经血管导丝、通桥麒麟血流导向密网支架、UltraFree药物洗脱PTA球囊扩张导管、ZYLOX Octoplus腔静脉滤器等产品销售规模大幅增长，市场渗透率稳步提升。在江苏省医用耗材集采接续采购 中，通桥凤颅内动脉瘤栓塞弹簧圈顺利完成续标。截至目前，公司已建立广泛的分销网络，覆盖超过 3000家医院。公司产品自商业化以来，在临床场景的使用数量已经突破100万个，持续为全球患者带去 高质量且可负担的产品和解决方案。 在持续推进成熟产品商业化落地的同时，归创通桥称，公司坚持差异化创新以更好满足未被满足的临床 需求。今年以来，ZYLOX Eagle血栓抽吸系统、通桥舜 ...

研发开支同比增长19.7%至人民币1.216亿元，用于新产品上市和产品管线创新。国际业务收入同比增长 36.9%，产品已覆盖全球7个TOP10市场。 公司已与超过60家当地伙伴建立战略合作，渠道覆盖全球52个国家及地区。公司在欧洲积极开展CE标 志产品上市后临床跟踪试验，以提升质量认可度和品牌知名度，并获得了Asklepios、SANA等知名医院 集团的支持。 归创通桥公布，2025年上半年，归创通桥实现收入人民币4.82亿元，同比增长31.7%，主要得益于神经 血管和外周血管介入器械分部的销售增长。公司净利润同比增长76%至人民币1.212亿元，经调整后净 利润增长68.1%至人民币1.314亿元。 ...

Major Events - CSPC Pharmaceutical Group (01093) received clinical trial approval for Dupilumab injection in China [1] - Rongchang Biopharmaceutical (09995) was granted breakthrough therapy designation for RC148 for non-small cell lung cancer by the National Medical Products Administration [1] - China Biologic Products (01177) included LM-302 "CLDN18.2 ADC" in the breakthrough therapy program [1] - Sunshine Oilsands (02012) plans to acquire 51% stake in Noble Technology Limited for HKD 50.91945 million [1] - Galenica Pharmaceutical-B (01672) plans to issue shares at a discount of approximately 9.9%, raising HKD 468 million [1] Financial Performance - Xiaomi Group-W (01810) reported record high revenue and profit for Q2, with attributable profit of HKD 11.904 billion, up 133.51% year-on-year [1] - Pop Mart (09992) announced a mid-term profit of HKD 4.574 billion, a year-on-year increase of 396.5% [1] - Fuyao Glass (03606) reported a half-year net profit of approximately HKD 4.805 billion, up 37.33% year-on-year [1] - China Resources Beer (00291) announced a mid-term profit of HKD 5.789 billion, an increase of 23.04% year-on-year [1] - Kunlun Energy (00135) reported a mid-term profit of HKD 3.161 billion, down 4.36% year-on-year, with a dividend of HKD 0.166 per share [1] - WuXi Biologics (02269) reported a mid-term profit of approximately HKD 2.339 billion, up 56% year-on-year [1] - Sunny Optical Technology (02382) announced a mid-term profit of HKD 1.646 billion, an increase of 52.56% year-on-year [1] - Yixin Group (02858) reported an adjusted net profit of HKD 648 million, up 28% year-on-year [1] - Kangchen Pharmaceutical (01681) reported a mid-term profit of HKD 498 million, up 24.6% year-on-year, maintaining market leadership with its flagship product [1] - Ping An Good Doctor (01833) reported a mid-term profit of HKD 134 million, a year-on-year increase of 136.84% [1] - China Communication Services (02342) reported a mid-term profit of HKD 61.781 million, returning to profitability [1] - XPeng Motors-W (09868) achieved record levels in core business and financial metrics for Q2, with a net loss of HKD 480 million, narrowing by 62.8% year-on-year [1] - Guochuang Tongqiao (02190) reported a mid-term profit of HKD 121 million, up 76% year-on-year [1] - Yanda Pharmaceutical (00512) reported record revenue of HKD 6.107 billion [1] - Jinli Permanent Magnet (06680) reported a mid-term profit of approximately HKD 305 million, up 154.81% year-on-year [1] - Zhaogang Group-W (06676) issued a profit warning, expecting a mid-term profit of approximately HKD 140 million to HKD 180 million, returning to profitability [1] - Longyuan Power (00916) reported a mid-term profit of HKD 3.519 billion, down 14.4% year-on-year [1] - Yancoal Australia (03668) reported a mid-term profit of AUD 16.3 million, down 61.19% year-on-year [1] - SF Holding (06936) reported total revenue of HKD 24.847 billion for July in logistics, supply chain, and international business, up 9.95% year-on-year [1] - Chow Sang Sang (00116) expects a mid-term profit from continuing operations of approximately HKD 900 million to HKD 920 million [1]

从业务板块来看，归创通桥上半年神经血管介入业务实现收入约3.04亿元，同比增长25%；外周血管介 入业务实现收入约1.76亿元，同比增长46.2%。海外业务实现营业收入1572万元，公司已有22款产品在 27个海外国家及地区实现商业化，超31款产品在23个国家及地区推进注册，海外渠道覆盖全球52个国家 和地区，并与超过60家当地合作伙伴建立合作。（智通财经记者 李潇潇） 8月19日，归创通桥医疗科技股份有限公司（2190.HK）发布2025年中期业绩公告。上半年营业收入4.82 亿元，同比增长31.7%；净利润突破1.21亿元，同比增长76%。 ...